Background: Cabozantinib, a potent multityrosine kinases inhibitor (TKI), has demonstrated overall survival (OS) benefit over everolimus in patients previously treated with VEGFR TKI for metastatic Renal Cell Carcinoma (mRCC). The efficacy of systemic treatments after cabozantinib failure has not been investigated.
Materials And Methods: We conducted a retrospective study on patients receiving systemic treatment after cabozantinib failure in heavily pretreated patient with mRCC. We assessed Time to Treatment Failure (TTF), OS and objective response rate (ORR).
Results: Among 150 patients treated with cabozantinib in our institution, 56 (37.3%) received subsequent systemic therapy and were eligible for the analysis. IMDC prognostic group was good, intermediate and poor in 11 (19.6%), 24 (42.9%) and 11 (19.6%) patients, respectively. Cabozantinib was administered mainly as a second (41.1%), or third (33.9%) line treatment. axitinib or immune-checkpoint inhibitors were the subsequent treatment in 18 (34.8%) patients for each everolimus (n:16, 28.6%), other angiogenesis inhibitors (n:4, 7.1%) TTF and OS from subsequent systemic therapy after cabozantinib failure were 2.8 months (95%CI 1.9-3.7) and 7.7 months (95%CI 4.4-10.8), respectively. ORR was 8.7% and 2 patients with axitinib and 2 patients treated with Immune checkpoint inhibitors achieved a partial response.
Conclusion: Overall, activity of systemic therapies after cabozantinib was limited.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clgc.2021.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reduction of bleeding by cabozantinib in metastatic renal cell carcinoma with hereditary hemorrhagic telangiectasia.
Int Cancer Conf J
January 2025
Department of Urology, Kobe University Graduate School of Medicine, 7-51 Kusunoki-cho, Kobe, Japan.
Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic disorder characterized by refractory recurrent epistaxis and gastrointestinal bleeding. Recent studies have reported the hemostatic effects of tyrosine kinase inhibitors on HHT-related bleeding. A 67-year-old man with HHT underwent laparoscopic radical nephrectomy for right renal cell carcinoma discovered during an investigation of anemia.
View Article and Find Full Text PDFAcquired reactive perforating collagenosis secondary to Cabozantinib: A case report and literature review.
SAGE Open Med Case Rep
December 2024
Division of Dermatology, University of Calgary, Calgary, AB, Canada.
Acquired perforating dermatoses (APD) encompass a group of skin conditions distinguished by transepidermal elimination of dermal components. Acquired reactive perforating collagenosis (ARPC), a subtype of APD, has been reported most commonly in association with diabetes mellitus, chronic renal failure, and medications. In this report, we identify a novel case of ARPC secondary to Cabozantinib treatment.
View Article and Find Full Text PDFUnveiling the Hidden Cause: A Case of Persistent Dysphagia.
Cureus
October 2024
Department of Internal Medicine, City of Hope Comprehensive Cancer Center, Duarte, USA.
Article Synopsis
- * The patient had a history of metastatic kidney cancer and developed swallowing difficulties months after his surgery, which were confirmed through various medical imaging tests.
- * Successful endoscopic surgery was performed to remove the screw, resolving the patient's dysphagia without any postoperative complications, highlighting the need for quick identification and teamwork in treatment.
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Cell Commun Signal
September 2024
Department of Thyroid Surgery, Zhejiang Cancer Hospital, No. 1 East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, China.
Article Synopsis
- * Standard treatment for early-stage MTC is surgery, with a 10-year survival rate over 80%, while metastatic cases face lower survival rates (10-40%) and limited effective therapies.
- * Recent advancements in targeted therapies, particularly RET inhibitors like Cabozantinib, Vandetanib, Selpercatinib, and Pralsetinib, offer new hope, though challenges such as drug resistance and side effects still complicate treatment for advanced MTC.
Background: The selection of appropriate second-line therapy for liver cancer after first-line treatment failure poses a significant clinical challenge due to the lack of direct comparative studies and standard treatment protocols. A network meta-analysis (NMA) provides a robust method to systematically evaluate the clinical outcomes and adverse effects of various second-line treatments for hepatocellular carcinoma (HCC).
Methods: We systematically searched PubMed, Embase, Web of Science and the Cochrane Library to identify phase III/IV randomized controlled trials (RCTs) published up to March 11, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!